Pharma News

Restricted access

The National Institute for Health and Care Excellence (NICE) in the United Kingdom (UK) has published draft guidelines for a new renal cell carcinoma treatment. The guidelines support the use of EUSA Pharma’s (Hemel Hempstead, England) Fotivda (tivozanib) as a first-line treatment option for advanced renal cell carcinoma. NICE provides national evidence-based guidance and quality standards to practitioners in the National Health Service.

In clinical trials, patients treated with Fotivda experienced longer progression-free survival—11.9 versus 9.1 months—in the overall population compared with those taking Bayer’s Nexavar (sorafenib). The drug also reduced side effects: 14% of patients on Fotivda compared with